BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 16210036)

  • 1. Essential thrombocythemia.
    Finazzi G; Harrison C
    Semin Hematol; 2005 Oct; 42(4):230-8. PubMed ID: 16210036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T; Finazzi G
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G; Barbui T
    Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential thrombocythemia.
    Brière JB
    Orphanet J Rare Dis; 2007 Jan; 2():3. PubMed ID: 17210076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G; Barbui T
    Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical parameters for determining when and when not to treat essential thrombocythemia.
    Barbui T; Finazzi G
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):14-8. PubMed ID: 9930552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A management program for primary thrombocytopenia].
    Knutsen H; Bruserud O
    Tidsskr Nor Laegeforen; 1999 Sep; 119(23):3431-4. PubMed ID: 10553341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management.
    Tefferi A; Murphy S
    Blood Rev; 2001 Sep; 15(3):121-31. PubMed ID: 11735160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired thrombophilia in pregnancy: essential thrombocythemia.
    Griesshammer M; Grünewald M; Michiels JJ
    Semin Thromb Hemost; 2003 Apr; 29(2):205-12. PubMed ID: 12709924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy.
    Griesshammer M; Struve S; Barbui T
    Blood Rev; 2008 Sep; 22(5):235-45. PubMed ID: 18617299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.
    Barbui T; Finazzi G
    Curr Hematol Rep; 2003 May; 2(3):248-56. PubMed ID: 12901347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC).
    Sacchi S; Vinci G; Gugliotta L; Rupoli S; Gargantini L; Martinelli V; Baravelli S; Lazzarino M; Finazzi G
    Haematologica; 2000 May; 85(5):492-5. PubMed ID: 10800165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to manage essential thrombocythemia.
    Finazzi G
    Leukemia; 2012 May; 26(5):875-82. PubMed ID: 22051530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
    Murphy S
    Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe.
    Griesshammer M; Struve S; Harrison CM
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):422-9. PubMed ID: 16810618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia.
    Radaelli F; Colombi M; Calori R; Zilioli VR; Bramanti S; Iurlo A; Zanella A
    Hematol Oncol; 2007 Sep; 25(3):115-20. PubMed ID: 17464935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis and treatment of essential thrombocythemia].
    Kuramoto A
    Rinsho Ketsueki; 1995 May; 36(5):480-6. PubMed ID: 7783354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Primary thrombocythemia: diagnosis and therapy].
    Petrides PE
    Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.